Post-kala-azar dermal leishmaniasis (PKDL) follows visceral leishmaniasis (VL, kala-azar)
in 10–60% of cases. It is characterized by an asymptomatic skin rash, usually starting in the …

Semiquantitative reverse-transcription polymerase chain reaction was used to analyze
intralesional cytokine gene expression in 28 patients with post–kala azar dermal …

Some patients develop post-kala-azar dermal leishmaniasis (PKDL) after they have been
treated for the systemic infection kala-azar (visceral leishmaniasis). It has been an enigma …

Post kala-azar dermal leishmaniasis (PKDL) is a dermatosis caused by persistence of
Leishmania donovani parasites in the skin following apparently successful treatment of …

Post–kala-azar dermal leishmaniasis (PKDL) has important public health implications for
transmission of visceral leishmaniasis (VL). Clinical and epidemiologic profiles of 102 PKDL …

Leishmaniasis is a neglected tropical disease that affects 12 million people worldwide. The
disease has high morbidity and mortality rates and is prevalent in over 80 countries, leaving …

Leishmaniasis remains a public health concern around the world that primarily affects poor
folks of the developing world spanning across 98 countries with mortality of 0.2 million to 0.4 …

Post kala-azar dermal leishmaniasis (PKDL) is a neglected complication of visceral
leishmaniasis (VL)―a deadly, infectious disease that claims approximately 20,000 to 40,000 …

Post-kala-azar dermal leishmaniasis (PKDL) is a recognized dermatosis that follows
successful treatment of visceral leishmaniasis in the Sudan. This randomized and double …

We conducted active surveillance for kala-azar and post–kala-azar dermal leishmaniasis
(PKDL) in a population of 24,814 individuals. Between 2002 and 2010, 1,002 kala-azar and …